Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation
MOUNTAIN VIEW, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) — Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its successful advocacy for revision of the recently issued Medicare Local Coverage Determinations (LCDs) for Cyclophotocoagulation (CPC).
Related news for (IRIX)
- Iridex Announces Preliminary Operational and Financial Results for the First Quarter 2025
- Iridex Reports Fourth Quarter and Full Year 2024 Financial Results
- Iridex Announces Strategic Investment in the Company
- Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2024
- Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management